Abstract:ObjectivesUsing quantitative coronary angiography (QCA), optical coherence tomography (OCT), histomorphometry, and pharmacokinetics, this study tried to evaluate the safety and efficacy of Biomagic rapamycin-eluting bioabsorbable scaffold (BVS) in non-atherosclerotic porcine coronary arteries.BackgroundBiomagic BVS is a new generation of thin-strut bioabsorbable scaffold. We conducted comparative study detailing pathological response, safety and efficacy of Biomagic BVS and the Firebird2 rapamycin-eluting cobalt-based alloy stent (DES) in a porcine coronary artery model. The animals were followed up at 14 days, 1, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months after stent implantation.MethodsA total of 143 devices (95 Biomagic and 48 Firebird2) were implanted in 2 or 3 main coronary arteries of 76 nonatherosclerotic swine and examined by QCA, OCT, light microscopy, and pharmacokinetics analyses at various time points.ResultsVascular responses to Biomagic and Firebird2 were largely comparable at all time points, with struts being sequestered within the neointima. The degree of inflammation of both devices was mild to moderate, although the Biomagic score was higher at 14 days to 24 months. However, there was no statistical difference between the two groups except 14 days. At each follow-up time point, the percentage of area stenosis in the Biomagic group was greater than that in the Firebird 2 group, but there was no statistical difference between the two groups at 3 and 12 months. The extent of fibrin deposition was similar between Biomagic and Firebird2, which peaked at 1 month and decreased rapidly thereafter. Pharmacokinetic study showed that coronary tissue sirolimus concentration remained above 2 ng/mg of tissue at 28 day. Histomorphometry showed expansile remodeling of Biomagic-implanted arteries starting after 12 months, and lumen area was significantly greater in Biomagic than Firebird2 at 36 and 42 months. These changes correlated with dismantling of Biomagic seen after 12 months. OCT images confirmed that degradation of Biomagic was complete by 36 months.ConclusionsBiomagic demonstrates comparable long-term safety to Firebird2 in porcine coronary arteries with mild to moderate inflammation. Although Biomagic was associated with greater percent stenosis relative to Firebird2 within 36 months, expansile remodeling was observed after 12 months in Biomagic with significantly greater lumen area at ≥36 months. Scaffold resorption is considered complete at 36 months.

6-Month Follow-Up of a Novel Biodegradable Drug-Eluting Stent Composed of Poly-L-Lactic Acid and Amorphous Calcium Phosphate Nanoparticles in Porcine Coronary Artery.

Mid-Term Outcomes of Novel Covered Stent with Biodegradable Membrane in Porcine Coronary Artery Perforation

Comparison of the “late Catch-Up” Phenomenon Between BuMA Supreme and XIENCE Stents Through Serial Optical Coherence Tomography at 1–2 Month and 2 Year Follow-Ups: A Multicenter Study

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Short-term Effects of Fully Bioabsorbable PLLA Coronary Stents in a Porcine Model

Long-Term Efficacy of Biodegradable Metal-Polymer Composite Stents after the First and the Second Implantations into Porcine Coronary Arteries

Long-Term Effects of Novel Biodegradable, Polymer-Coated, Sirolimus-Eluting Stents on Neointimal Formation in A Porcine Coronary Model

A novel biodegradable polymer coated,sirolimus-eluting stent: evaluation in a porcine coronary model

A novel biodegradable polymer-coated cobalt-chromium alloy sirolimus-eluting stent：evaluation in a porcine model

Long-term in vivo study of biodegradable Zn-Cu stent: A 2-year implantation evaluation in porcine coronary artery.

Efficacy and Safety of a Novel Nano-Porous Polymer-Free Sirolimus-Eluting Stent in Pigs.

Five-year Comparative Study of Thin-Strut Rapamycin-Eluting Bioabsorbable Scaffold with Metallic Drug-Eluting Stent in Porcine Coronary Artery

A Biodegradable-Polymer-plga-coated,sirolimus-eluting Cobalt-chromium Alloy Stent:Safety and Efficacy Evaluation in a Porcine Model

Drug-Eluting Biodegradable Poly-D/L-Lactic Acid Vascular Stents: An Experimental Pilot Study

A Novel Paclitaxel Eluting Bioresorbable Coronary Stent 3D Printed from a Tougher and Faster Degradation Poly(L-Lactide-Co-Caprolactone) Co-Polymer

Assessment of an Asymmetrical Coating Stent with Sirolimus Released from Ablumial Matrix in Porcine Model

Safety and Efficacy of Cobalt Chromium Alloy Based Sirolimus-Eluting Stent with Bioabsorbable Polymer in Porcine Model.

Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications

Polymer-free Dual Drug-Eluting Stents Evaluated in a Porcine Model

AS-30: the Preclinical Assessment of a Novel Biodegradable Rapid Prohealing Polymer with Sirolimus -Eluting Coating Stent in Porcine Model

A cell membrane like biomimetic drug-eluting coronary stent